This company has been marked as potentially delisted and may not be actively trading. GTX (GTXI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock GTXI vs. SABS, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying GTX stock or one of its competitors? The main competitors of GTX include SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. GTX vs. SAB Biotherapeutics Curis Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen GTX (NASDAQ:GTXI) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Does the MarketBeat Community believe in GTXI or SABS? GTX received 284 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 83.78% of users gave SAB Biotherapeutics an outperform vote while only 73.60% of users gave GTX an outperform vote. CompanyUnderperformOutperformGTXOutperform Votes31573.60% Underperform Votes11326.40% SAB BiotherapeuticsOutperform Votes3183.78% Underperform Votes616.22% Is GTXI or SABS more profitable? GTX has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,450.14%. SAB Biotherapeutics' return on equity of -94.37% beat GTX's return on equity.Company Net Margins Return on Equity Return on Assets GTXN/A -104.19% -86.42% SAB Biotherapeutics -1,450.14%-94.37%-67.26% Which has better valuation & earnings, GTXI or SABS? GTX has higher earnings, but lower revenue than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than GTX, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGTXN/AN/A-$38.42M-$1.65-0.32SAB Biotherapeutics$2.24M6.64-$42.19M-$3.68-0.43 Do institutionals and insiders hold more shares of GTXI or SABS? 9.5% of GTX shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 40.9% of GTX shares are held by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate GTXI or SABS? SAB Biotherapeutics has a consensus price target of $11.40, indicating a potential upside of 612.50%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than GTX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GTX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GTXI or SABS? In the previous week, GTX had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for GTX and 2 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.33 beat GTX's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GTX 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, GTXI or SABS? GTX has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. SummaryGTX beats SAB Biotherapeutics on 9 of the 17 factors compared between the two stocks. Get GTX News Delivered to You Automatically Sign up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTXI vs. The Competition Export to ExcelMetricGTXPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.67M$6.86B$5.56B$8.03BDividend YieldN/A2.91%5.07%4.23%P/E Ratio-0.327.5422.7918.88Price / SalesN/A259.65406.23106.93Price / CashN/A65.8538.1834.62Price / Book0.486.566.794.34Net Income-$38.42M$143.88M$3.23B$248.14M GTX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTXIGTXN/A$0.53flatN/AN/A$12.67MN/A-0.3221SABSSAB Biotherapeutics3.2615 of 5 stars$1.66-7.5%$11.40+588.8%-60.3%$15.37M$2.24M-0.45140Short Interest ↓News CoverageGap DownCRISCuris2.6016 of 5 stars$1.81-2.7%$21.00+1,060.2%-85.3%$15.36M$10.91M-0.2360Upcoming EarningsAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap UpBOLTBolt Biotherapeutics2.533 of 5 stars$0.37-1.4%$1.13+208.2%-67.9%$13.99M$7.69M-0.2190Short Interest ↑Gap UpMTEMMolecular Templates1.0244 of 5 starsN/AN/AN/A$1,000.00$23.48M0.00260AMGNAmgen4.0905 of 5 stars$288.56+1.9%$310.57+7.6%-9.7%$155.14B$33.42B38.2225,200Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsGap UpGILDGilead Sciences4.7874 of 5 stars$104.21-2.0%$109.43+5.0%+60.0%$129.76B$28.74B281.6517,000Dividend AnnouncementVRTXVertex Pharmaceuticals3.9671 of 5 stars$503.50+1.4%$514.91+2.3%+25.0%$129.29B$11.02B-228.864,800Upcoming EarningsPositive NewsREGNRegeneron Pharmaceuticals4.8375 of 5 stars$568.91-6.9%$945.32+66.2%-36.7%$62.20B$14.20B14.8611,900Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeALNYAlnylam Pharmaceuticals4.1204 of 5 stars$257.19+0.9%$315.58+22.7%+70.3%$33.46B$2.25B-118.522,000Earnings ReportAnalyst DowngradeNews CoverageBIIBBiogen4.7038 of 5 stars$120.17+0.9%$201.93+68.0%-43.2%$17.59B$9.68B10.748,720Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies SAB Biotherapeutics Competitors Curis Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTXI) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GTX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GTXI Stock Free GTXI Stock Alerts